The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize
Industry Leaders Back At The Wheel Are Driving Health Care Transformation
Executive Summary
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.
You may also be interested in...
Medtronic Looks Beyond The World Of Doctors And Devices In New Approach To Markets
Focus On Switzerland – Part 2. Health warning to global medtechs: the world’s largest medtech company is taking steps to strengthen key account management, retain its market share hold and set up new health care partnerships.
AI Medical Imaging And Radiotherapy First For UK’s NICE
Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.
CMR Surgical Targeting New RAS Procedures And Markets For Growth
Marcio Coelho, chef commercial officer of robotic assisted surgery company CMR Surgical, updated In Vivo on the company’s unique approach to expanding uptake of its technologies in global markets, including those that are underserved in RAS devices.